Eikon Therapeutics, Inc. Common Stock (EIKN) - Total Assets
Based on the latest financial reports, Eikon Therapeutics, Inc. Common Stock (EIKN) holds total assets worth $594.73 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See EIKN net asset value for net asset value and shareholders' equity analysis.
Eikon Therapeutics, Inc. Common Stock - Total Assets Trend (2023–2025)
This chart illustrates how Eikon Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
Eikon Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Eikon Therapeutics, Inc. Common Stock's total assets of $594.73 Million consist of 58.7% current assets and 41.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2023–2025)
This chart illustrates how Eikon Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Eikon Therapeutics, Inc. Common Stock market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eikon Therapeutics, Inc. Common Stock's current assets represent 58.7% of total assets in 2025, a decrease from 83.0% in 2023.
- Cash Position: Cash and equivalents constituted 17.6% of total assets in 2025, down from 21.5% in 2023.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2023.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Eikon Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Eikon Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Synlogic Inc
NASDAQ:SYBX
|
USA | $15.45 Million |
|
Entero Therapeutics, Inc.
NASDAQ:GRDX
|
USA | $135.37 Million |
|
Vyome Holdings, Inc.
NASDAQ:HIND
|
USA | $7.05 Million |
|
Applied Therapeutics Inc
NASDAQ:APLT
|
USA | $34.37 Million |
|
Cellectar Biosciences Inc
NASDAQ:CLRB
|
USA | $14.98 Million |
|
Intensity Therapeutics, Inc. Common stock
NASDAQ:INTS
|
USA | $12.29 Million |
|
TNF Pharmaceuticals, Inc.
NASDAQ:TNFA
|
USA | $17.15 Million |
|
Hepion Pharmaceuticals Inc
NASDAQ:HEPA
|
USA | $3.07 Million |
Eikon Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.34 | 4.04 | 4.04 |
| Quick Ratio | 6.34 | 4.04 | 4.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $293.91 Million | $171.44 Million | $171.44 Million |
Eikon Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Eikon Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.91 |
| Asset Growth Rate (YoY) | 21.1% |
| Total Assets | $594.73 Million |
| Market Capitalization | $538.68 Million USD |
Valuation Analysis
Near Book Valuation: The market values Eikon Therapeutics, Inc. Common Stock's assets close to their book value (0.91x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Eikon Therapeutics, Inc. Common Stock's assets grew by 21.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Eikon Therapeutics, Inc. Common Stock (2023–2025)
The table below shows the annual total assets of Eikon Therapeutics, Inc. Common Stock from 2023 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $594.73 Million | +21.07% |
| 2024-12-31 | $491.24 Million | -6.56% |
| 2023-12-31 | $525.71 Million | -- |
About Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and… Read more